| Document |
Document Title |
|
WO/2024/103025A1 |
The disclosure provides methods and tools allowing production of large quantities of double stranded RNA (dsRNA) in bacterial cells, including plasmid vectors useful for transforming gram-positive or gram-negative bacterial cells such th...
|
|
WO/2024/100145A1 |
A polynucleotide comprising a nucleotide sequence encoding an engineered sacsin, wherein the engineered sacsin comprises a UbL domain or variant thereof, an SRR domain or variant thereof, a DnaJ domain or variant thereof and an HERN doma...
|
|
WO/2024/100548A1 |
The present invention relates to the medical use of a compound in the treatment of tumor metastases.
|
|
WO/2024/073595A3 |
The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a Huntingtin (HTT) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucl...
|
|
WO/2024/098193A1 |
Provided is a use of mitochondrial fusion protein 2 (MFN2), an MFN2 variant capable of interacting with SERCA2, or an MFN2 expression promoter in maintaining and/or promoting tumor killing and/or viability of a CD8 T cell. Also provided ...
|
|
WO/2024/100137A1 |
Non-human animal-derived cell composition comprising a plurality of non-human animal- derived cells, wherein the cells comprise at least one exogenous supplement comprised in a carrier selected from the group consisting of nanocarriers, ...
|
|
WO/2024/101406A1 |
The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) or liver cancer, the agent containing a material for inhibiting the expression or f...
|
|
WO/2024/072224A3 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/076725A3 |
Disclosed are self-regulated chimeric antigen receptors and methods of making the same. Also, disclosed herein are methods of treating a cancer through the administration of NK cells and/or NK T cells comprising said chimeric antigen rec...
|
|
WO/2024/102417A2 |
|
|
WO/2024/076967A9 |
The present invention provides compositions and methods for reducing the level and/or activity of a TET protein, for treating or preventing a disease and disorder associated with an increased level and/or activity of a TET protein, for r...
|
|
WO/2024/064901A3 |
The present invention relates to processes for producing ethanol comprising saccharifying cellulosic or starch-containing material and fermenting the saccharified material with a fermenting microorganism to produce ethanol. The fermentin...
|
|
WO/2024/103042A1 |
The present disclosure is related to improved compositions and methods related to viral immunotherapy treatments for cancer. Specifically, provided herein are therapeutic rAAV vectors, particles, and compositions thereof related to treat...
|
|
WO/2024/102666A2 |
The disclosure relates generally to gene editing systems comprising large serine recombinases and methods of using such large serine recombinases for integration of nucleic acid sequences.
|
|
WO/2024/102277A2 |
Compositions and methods for altering flowering and/or maturity time of soybean plant are provided. Compositions include isolated and recombinant polynucleotides encoding polypeptides, expression cassettes, host cells, plants, plant part...
|
|
WO/2024/103060A1 |
This invention is directed to peanut plants or parts thereof comprising at least one mutation in one or more β-ketoacyl-ACP synthetase II (KASII) genes encoding a KasII polypeptide and methods and compositions for making and using the s...
|
|
WO/2024/101755A1 |
The present disclosure relates to a novel method for preparing Taq DNA polymerase, and more specifically, to a method for preparing Taq DNA polymerase in Pichia pastoris, Taq DNA polymerase produced thereby, and a method for amplifying o...
|
|
WO/2024/015935A3 |
Disclosed herein are compositions comprising at least one extracellular vesicle, wherein the at least one extracellular vesicle comprises a polypeptide of a first pathogen antigen or a fragment thereof on the surface of the at least one ...
|
|
WO/2024/100292A1 |
The present invention provides a new method that is specifically designed to start statistically from a single copy of a nucleic acid molecule and requires only a single encapsulation step to provide clonal microcompartment libraries dis...
|
|
WO/2024/064633A3 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6215 and methods and uses thereof, or inactivati...
|
|
WO/2024/102943A1 |
Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/102454A1 |
This document relates to methods and materials involved in producing antibodies (e.g., single domain antibody (sdAbs) and/or heavy chain only antibodies) having one or two chimeric heavy chains. For example, (A) genetically engineered no...
|
|
WO/2024/101915A1 |
The present invention relates to a peptide nucleic acid complex having enhanced stability and improved inhibitory effects on a target gene, wherein the terminals of a bioactive peptide nucleic acid and a carrier peptide nucleic acid are ...
|
|
WO/2024/098383A1 |
Disclosed are a protein mutant with a sequence having more than 80% identity to SEQ ID NO. 1, a gRNA used in combination with the protein mutant, a gene editing system, an expression vector, a modified cell, a pharmaceutical composition,...
|
|
WO/2024/100633A1 |
The disclosure describes improved vectors, such as adeno-associated virus (AAV) vectors, for expressing progranulin and variants thereof in transduced cells, and use of such vectors to increase the amount of progranulin in subjects exper...
|
|
WO/2024/099865A1 |
The present invention refers to a cell suspension of autologous adult bone marrow-derived mononuclear cells for use in the treatment or amelioration of a subject suffering or having suffered from an ischemic or a hemorrhagic stroke and m...
|
|
WO/2024/100392A1 |
The present invention provides novel drug-inducible degradation tags (degrons), as well as fusion proteins, cells and pharmaceutical compositions comprising the same. Nucleic acid sequences and vectors encoding the novel degrons are also...
|
|
WO/2024/101063A1 |
Provided is a PHA polymerization enzyme that has high substrate specificity and makes it possible to synthesize a PHA that has a comparatively high molecular weight. A production method for a polyhydroxyalkanoate according to the prese...
|
|
WO/2024/102958A1 |
Provided herein are methods and compositions for processing a target nucleic acid sequence. The methods and compositions provided herein comprise a guide complex for recruiting an enzyme which can introduce a cut on the target nucleic ac...
|
|
WO/2024/098448A1 |
Provided is an embryo culture solution-based non-invasive screening method for preimplantation embryos. Methylation detection is carried out on cell-free DNAs in a culture solution of preimplantation embryos to be detected, and according...
|
|
WO/2024/077165A3 |
Disclosed herein are system, apparatus, method, and/or computer program product embodiments, and/or combinations and sub-combinations thereof which enables 3D base calling using flow cell images of samples such as in situ cells or tissue...
|
|
WO/2024/064709A3 |
Provided herein is a conditionally-replicating serotype 5 adenovirus or adenoviral vector expressing a mutant E1A protein under control of a promoter that is responsive to hypoxia and inflammation and one or more immune modulators under ...
|
|
WO/2024/101357A1 |
An antibody against coatomer protein complex subunit beta 2 (COPB2) or an antigen-binding fragment thereof that contains any of CDR sets (a) to (c): (a) a heavy chain CDR1 comprising an amino acid sequence represented by SEQ ID NO: 1, a ...
|
|
WO/2024/098498A1 |
The present invention relates to an mRNA for encoding an anti-avian influenza H7N9 virus antibody, a preparation method therefor, and use thereof. Specifically, provided is an isolated mRNA composition, which comprises an mRNA comprising...
|
|
WO/2024/081738A3 |
The present disclosure provides systems, compositions, and methods for nucleic acid modification. More particularly, the present disclosure provides systems comprising a TnpA protein, a TnpB protein, an IscB protein, or a combination the...
|
|
WO/2024/098242A1 |
Disclosed are a method for detecting milk production properties of dairy cows using an APOM gene SNPs molecular marker and use. The present invention provides use of a substance for detecting genotypes of the following four SNP sites in ...
|
|
WO/2024/077110A3 |
The present disclosure provides isolated polynucleotides comprising sequences encoding uORF peptides and variants and fragments thereof. The present disclosure also provides constructs and vectors containing the polynucleotides. The pres...
|
|
WO/2023/215321A3 |
Polynucleotide compositions comprising (a) a complementary oligonucleotide comprising at least 10 consecutive nucleobases having at least 80% complementarity to a target gene having a premature UGA stop codon; (b) an optional linker sele...
|
|
WO/2024/102764A1 |
The disclosure relates to methods of treating cancer in a subject administering nucleic acid molecules comprising a nucleic acid sequence encoding a plurality of neoantigens. Vaccines, compositions comprising coding regions encoding neoa...
|
|
WO/2024/102106A2 |
The present invention relates to a tool and method for targeted downregulation or upregulation of endogenous gene expressions in molecular biology, genetics, stem cell studies, gene therapy and biotechnology applications, developmental b...
|
|
WO/2024/099366A1 |
Disclosed is use of SlPIF4 as a negative regulatory factor in the improvement of melatonin content of tomato fruits. The content of melatonin in the tomato fruits is reduced by means of the overexpression of an SlPIF4 gene driven by a co...
|
|
WO/2024/099089A1 |
Provided are a genetically engineered strain for producing pseudouridine and use thereof in the fermentation and production of pseudouridine. The strain performs heterologous overexpression of a pyrimidine nucleoside operon, overexpressi...
|
|
WO/2024/098148A1 |
There is described herein modified T cells engineered to have decreased IRF2 expression and method of making and using the same for cancer therapy.
|
|
WO/2024/059699A3 |
Described herein are methods and compositions for generating single sex offspring using trans-splicing approach. In particular, methods and compositions are provided to generate single sex and genetically modified offspring. These techni...
|
|
WO/2024/098238A1 |
β-Hemoglobinopathies are hereditary diseases that originate from mutations in the hemoglobin beta (HBB) gene. The general inventive concepts are based on the discovery that hemoglobinopathies can be treated by administration of a dual v...
|
|
WO/2024/102923A1 |
The present disclosure provides a vaccine composition comprising six or more homologous distinct antigen components. Any two of the six or more homologous distinct antigen components may share less than 98% or 95% sequence identity. The ...
|
|
WO/2024/059778A3 |
Methods of modulating expression and / or secretion of at least one of IRG1, TNFα, IL-6, IL-1b, itaconate, CXCL-10, IRAK4, major histocompatibility complex II (MHC II), and NFκB in a subject and method of treating or preventing a disea...
|
|
WO/2024/073596A3 |
The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target an ataxin-3 (ATXN3) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internuc...
|
|
WO/2024/101942A1 |
The present invention relates to cells genetically engineered to express a peptide or a fragment thereof which can inhibit a transforming growth factor-β (TGF-β) signaling pathway.
|
|
WO/2024/101305A1 |
A culture vessel (10) comprises a container body (11) that has an opening (11a) that opens in a slit shape, and that vertically accommodates a sheet-like object (membrane filter (100)) through the opening (11a).
|
